Stille AB
STO:STIL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
144
247
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Stille AB
Cost of Revenue
Stille AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Stille AB
STO:STIL
|
Cost of Revenue
-kr247.8m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-17%
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Cost of Revenue
-kr11.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Cost of Revenue
-kr269.6m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Cost of Revenue
-kr243.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Getinge AB
STO:GETI B
|
Cost of Revenue
-kr17.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Cost of Revenue
-kr6.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Stille AB
Glance View
Stille AB engages in the development and sale of medical equipment. The company is headquartered in Torshaella, Sodermanlands. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.
See Also
What is Stille AB's Cost of Revenue?
Cost of Revenue
-247.8m
SEK
Based on the financial report for Sep 30, 2024, Stille AB's Cost of Revenue amounts to -247.8m SEK.
What is Stille AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-17%
Over the last year, the Cost of Revenue growth was -61%. The average annual Cost of Revenue growth rates for Stille AB have been -37% over the past three years , -22% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
